131 related articles for article (PubMed ID: 16012325)
1. Ara-C fever and infections after high-dose ara-C treatment in pediatric lymphoid malignancies.
Ek T; Pinkava M; Abrahamsson J
J Pediatr Hematol Oncol; 2005 Jul; 27(7):364-9. PubMed ID: 16012325
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of intermediate-dose methotrexate and cytosine arabinoside, "spread-out" or "up-front," in continuation therapy for childhood non-T, non-B acute lymphoblastic leukemia. A Pediatric Oncology Group study.
Krance RA; Newman EM; Ravindranath Y; Harris MB; Brecher M; Wimmer R; Shuster JJ; Land VJ; Pullen J; Crist W
Cancer; 1991 Feb; 67(3):550-6. PubMed ID: 1985748
[TBL] [Abstract][Full Text] [Related]
3. A randomized comparison of modified intermediate-dose Ara-C versus high-dose ara-c in post-remission therapy for acute myeloid leukemia.
Fukushima T; Urasaki Y; Yamaguchi M; Ueda M; Morinaga K; Haba T; Sugiyama T; Nakao S; Origasa H; Umehara H; Ueda T
Anticancer Res; 2012 Feb; 32(2):643-7. PubMed ID: 22287757
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Empiric Vancomycin for Fevers During High-dose Cytarabine Administration.
Hoover A; Zimmerman JAO; Wiese S; Modi A
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e1010-e1014. PubMed ID: 33560084
[TBL] [Abstract][Full Text] [Related]
5. High-dose cytarabine-containing chemotherapy with or without granulocyte colony-stimulating factor for children with acute leukemia.
Chen SH; Liang DC; Liu HC
Am J Hematol; 1998 May; 58(1):20-3. PubMed ID: 9590144
[TBL] [Abstract][Full Text] [Related]
6. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
[TBL] [Abstract][Full Text] [Related]
7. [Significance of C-reaction protein for differential diagnosis of fever after chemotherapy on children with acute lymphoblastic leukemia].
Fang CQ; Tang YM; Li HF; Song H; Shi SW; Yang SL; Xu WQ
Zhonghua Er Ke Za Zhi; 2004 Jul; 42(7):536-7. PubMed ID: 15324576
[No Abstract] [Full Text] [Related]
8. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
9. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665
[TBL] [Abstract][Full Text] [Related]
10. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency.
Smith GA; Damon LE; Rugo HS; Ries CA; Linker CA
J Clin Oncol; 1997 Feb; 15(2):833-9. PubMed ID: 9053511
[TBL] [Abstract][Full Text] [Related]
11. Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study.
Bowman WP; Shuster JJ; Cook B; Griffin T; Behm F; Pullen J; Link M; Head D; Carroll A; Berard C; Murphy S
J Clin Oncol; 1996 Apr; 14(4):1252-61. PubMed ID: 8648381
[TBL] [Abstract][Full Text] [Related]
12. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma.
Seymour JF; Grigg AP; Szer J; Fox RM
Cancer; 2002 Feb; 94(3):585-93. PubMed ID: 11857288
[TBL] [Abstract][Full Text] [Related]
14. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
Haematologica; 1997; 82(5 Suppl):19-22. PubMed ID: 9402749
[TBL] [Abstract][Full Text] [Related]
15. The predictive and diagnostic values of procalcitonin and C-reactive protein for clinical outcome in febrile neutropenic patients.
Erten N; Genc S; Besisik SK; Saka B; Karan MA; Tascioglu C
J Chin Med Assoc; 2004 May; 67(5):217-21. PubMed ID: 15357107
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Hofmann WK; Seipelt G; Langenhan S; Reutzel R; Schott D; Schoeffski O; Illiger HJ; Hartmann F; Balleisen L; Franke A; Fiedler F; Huber C; Rasche H; Bergmann L; Ganser A; Pott C; Pasold R; Rudolph C; Ottmann OG; Gökbuget N; Hoelzer D
Ann Hematol; 2002 Oct; 81(10):570-4. PubMed ID: 12424538
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia.
Clarke V; Dunstan FD; Webb DK
Med Pediatr Oncol; 1999 May; 32(5):331-5. PubMed ID: 10219333
[TBL] [Abstract][Full Text] [Related]
18. Role of procalcitonin and CRP in differentiating a stable from a deteriorating clinical course in pediatric febrile neutropenia.
Secmeer G; Devrim I; Kara A; Ceyhan M; Cengiz B; Kutluk T; Buyukpamukcu M; Yetgin S; Tuncer M; Uludag AK; Tezer H; Yildirim I
J Pediatr Hematol Oncol; 2007 Feb; 29(2):107-11. PubMed ID: 17279007
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein, procalcitonin and the lab-score for detecting serious bacterial infections in febrile children at the emergency department: a prospective observational study.
Nijman RG; Moll HA; Smit FJ; Gervaix A; Weerkamp F; Vergouwe Y; de Rijke YB; Oostenbrink R
Pediatr Infect Dis J; 2014 Nov; 33(11):e273-9. PubMed ID: 25093971
[TBL] [Abstract][Full Text] [Related]
20. Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma--a rationale for tailored supportive care.
Lex C; Körholz D; Kohlmüller B; Bönig H; Willers R; Kramm CM; Göbel U
Support Care Cancer; 2001 Oct; 9(7):514-21. PubMed ID: 11680831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
